Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Eisai announces results of perampanel Phase III study on epilepsy

Results presented today of a Phase III pivotal study for the investigational compound perampanel for partial-onset seizures showed that perampanel, 8 mg and 12 mg, produced statistically significant reductions in median seizure frequency compared to placebo among patients having partial-onset seizures while receiving treatment with one to three other epilepsy drugs.

31 Aug 2011

Symptom-based viral load testing detects HIV in MSM

Testing for HIV when flu-like symptoms develop may offer a cost-effective alternative for early detection of HIV infection in men who have sex with men (MSM), reports a study in the journal AIDS.

31 Aug 2011

FDA accepts Salix and Progenics' sNDA filing for RELISTOR to treat opioid-induced constipation

Progenics Pharmaceuticals, Inc. and Salix Pharmaceuticals, Ltd. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental New Drug Application (sNDA) for RELISTOR Subcutaneous Injection to treat opioid-induced constipation (OIC) in patients with non-cancer pain.

30 Aug 2011

Adimab initiates independent collaborations with Biogen Idec and Novo Nordisk

Adimab, LLC, a technology leader in the discovery of fully human antibodies, today announced the initiation of two independent collaborations with Biogen Idec and Novo Nordisk. Over the past two years, Adimab has established collaborations with multiple leading pharmaceutical companies, including: Merck, Roche, Novartis, Pfizer, Eli Lilly, Genentech, Human Genome Sciences, and now Biogen Idec and Novo Nordisk.

29 Aug 2011

Zymeworks, Merck collaborate to develop novel bi-specific antibody therapeutic candidates

Zymeworks Inc. today announced a research collaboration with Merck, known as MSD outside the United States and Canada, around Zymeworks' proprietary Azymetric platform for the development of novel bi-specific antibody therapeutic candidates. Bi-specific antibodies are designed to bind to two different drug targets for broad use in clinical applications such as oncology or autoimmune disease.

29 Aug 2011

Researchers reveal new gene associated with osteoarthritis

Researchers have today revealed a new gene associated with osteoarthritis. This is only the third gene to be identified for this painful and debilitating disease that affects more than 40 per cent of people aged more than 70 years.

26 Aug 2011

Emergent announces results of adjuvanted BioThrax anthrax vaccine Phase 1a trial

Emergent BioSolutions Inc. announced today that results from a Phase 1a clinical trial evaluating an investigational anthrax vaccine, Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant mixed at bedside, have been published in Vaccine, a leading medical journal on vaccines and immunology.

26 Aug 2011

Kinexus launches TranscriptoNET KnowledgeBase for human gene expression study

Kinexus Bioinformatics Corporation, a world-leader in molecular intelligence research, announced the launch of its TranscriptoNET KnowledgeBase for the study of human gene expression in over 300 types of human tissues and organs as well as over 300 human cancer cell lines.

25 Aug 2011

IMMY, University of Nevada receive FDA clearance for CrAg Lateral Flow Assay

The Food and Drug Administration has cleared a new diagnostic test that will help save the lives of hundreds of thousands of AIDS patients stricken with cryptococcosis, a fungal meningitis.

25 Aug 2011

Celldex announces key in vivo efficacy results of CDX-1135 in Dense Deposit Disease

Celldex Therapeutics, Inc. today announced key in vivo efficacy data for its CDX-1135 program from a collaboration with Drs. Richard Smith and Carla Nester at the University of Iowa.

24 Aug 2011

Seattle Genetics initiates ADCETRIS phase II trial in CD30-positive non-Hodgkin lymphoma

Seattle Genetics, Inc. today announced that it has initiated a phase II clinical trial of ADCETRIS for patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas, including diffuse large B-cell lymphoma, peripheral T-cell lymphoma and other less common lymphoma subtypes.

24 Aug 2011

Symphogen initiates Sym004 Phase 2 trial in squamous cell carcinoma of head and neck cancer

Symphogen A/S today announced the initiation of a Phase 2 clinical trial to investigate the safety and efficacy of Sym004 in patients who have failed anti-EGFR monoclonal antibody (mAb)-based therapy, with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

23 Aug 2011

Micro-organisms hide themselves from immune defences

That micro-organisms have a great capacity to vary their surface structure is well known. It is one of the reasons why it is so difficult to develop vaccines against HIV and malaria, and why new influenza vaccines have to be produced every year. But it seems that these micro-organisms are also able to completely avoid activating a strong immune response in the person attacked.

22 Aug 2011

Research on why and how malaria parasites go undetected in the placenta of pregnant women

Collaborative research between LSTM and the University of Copenhagen, published last week in the Proceedings of the National Academy of Sciences, have answered a long standing mystery, why and how malaria parasites go unnoticed by the immune defences of pregnant mothers.

20 Aug 2011

FDA approves Seattle Genetics ADCETRIS drug to treat Hodgkin lymphoma, ALCL

Seattle Genetics, Inc. today announced that the U.S. Food and Drug Administration has granted accelerated approval of ADCETRISTM for two indications: (1) the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and (2) the treatment of patients with systemic anaplastic large cell lymphoma after failure of at least one prior multi-agent chemotherapy regimen.

20 Aug 2011

Seattle Genetics receives FDA approval for Adcetris to treat Hodgkin lymphoma, ALCL

The U.S. Food and Drug Administration today approved Adcetris to treat Hodgkin lymphoma and a rare lymphoma known as systemic anaplastic large cell lymphoma.

20 Aug 2011

Researchers isolate 17 novel antibodies against HIV

A team of researchers at and associated with the International AIDS Vaccine Initiative (IAVI), The Scripps Research Institute, the biotechnology company Theraclone Sciences and Monogram Biosciences Inc., a LabCorp company, report in the current issue of Nature the isolation of 17 novel antibodies capable of neutralizing a broad spectrum of variants of HIV, the virus that causes AIDS.

18 Aug 2011

GeoVax receives NIH-NIAID grant for HIV/AIDS vaccine program

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced receipt of a $3.6 million annual notice of award for the Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) Grant supporting GeoVax's HIV/AIDS vaccine program.

17 Aug 2011

OrbusNeich's Genous Stent safe, effective for patients at high risk of restenosis

OrbusNeich today announced that the that the company's Genous Stent showed no significant difference in the rate of target vessel failure (TVF) at two years compared to the Taxus Liberte™ paclitaxel-eluting stent in patients with de novo coronary artery lesions carrying a high risk for restenosis.

17 Aug 2011

Researchers identify mesothelin antibody that could detect early-stage ovarian cancer

Using a new approach to developing biomarkers for the very early detection of ovarian cancer, researchers at Rush University Medical Center have identified a molecule in the bloodstream of infertile women that could one day be used to screen for those at high risk for the disease — or even those with early-stage ovarian cancer.

17 Aug 2011

Antibody News and Research

Further Reading

Eisai announces results of perampanel Phase III study on epilepsy

Symptom-based viral load testing detects HIV in MSM

FDA accepts Salix and Progenics' sNDA filing for RELISTOR to treat opioid-induced constipation

Adimab initiates independent collaborations with Biogen Idec and Novo Nordisk

Zymeworks, Merck collaborate to develop novel bi-specific antibody therapeutic candidates

Researchers reveal new gene associated with osteoarthritis

Emergent announces results of adjuvanted BioThrax anthrax vaccine Phase 1a trial

Kinexus launches TranscriptoNET KnowledgeBase for human gene expression study

IMMY, University of Nevada receive FDA clearance for CrAg Lateral Flow Assay

Celldex announces key in vivo efficacy results of CDX-1135 in Dense Deposit Disease

Seattle Genetics initiates ADCETRIS phase II trial in CD30-positive non-Hodgkin lymphoma

Symphogen initiates Sym004 Phase 2 trial in squamous cell carcinoma of head and neck cancer

Micro-organisms hide themselves from immune defences

Research on why and how malaria parasites go undetected in the placenta of pregnant women

FDA approves Seattle Genetics ADCETRIS drug to treat Hodgkin lymphoma, ALCL

Seattle Genetics receives FDA approval for Adcetris to treat Hodgkin lymphoma, ALCL

Researchers isolate 17 novel antibodies against HIV

GeoVax receives NIH-NIAID grant for HIV/AIDS vaccine program

OrbusNeich's Genous Stent safe, effective for patients at high risk of restenosis

Researchers identify mesothelin antibody that could detect early-stage ovarian cancer

Accelerating therapeutic antibody discovery and development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo